U.S. Pushes for Radiopharmaceutical Independence as Demand Surges
As global demand for radiopharmaceuticals and nuclear medicine continues to accelerate, U.S.-based manufacturers are stepping up efforts to expand domestic production capacity and reduce reliance on foreign supply chains. Radiopharmaceuticals—radioactive compounds used in both the diagnosis and treatment of diseases, particularly cancer—are becoming an increasingly critical component of modern healthcare. In response, industry leaders like Cardinal Health and Shine Technologies are investing heavily in scaling up production within the United States.
Rising Demand for Radiopharmaceuticals
Radiopharmaceuticals play a vital role in oncology and other medical specialties by enabling highly targeted imaging and therapies. These compounds are designed to bind to specific cells in the body, allowing clinicians to both visualize disease progression and deliver precise radiation doses to affected areas. With cancer rates rising globally and precision medicine gaining traction, the demand for these treatments has grown significantly.
However, despite the U.S. being a pioneer in nuclear medicine technologies, the country has historically depended on international nuclear reactors for many key isotopes. This reliance has created vulnerabilities in the supply chain, including periodic shortages and logistical challenges that can delay patient care.
Cardinal Health Expands Actinium-225 Production
In a move aimed at strengthening domestic capabilities, Cardinal Health recently announced an expansion of its production of actinium-225 (Ac-225) at its facility in Indianapolis, Indiana. Actinium-225 is a highly sought-after radionuclide used in targeted alpha therapy, a cutting-edge cancer treatment that delivers powerful radiation directly to tumor cells while minimizing damage to surrounding healthy tissue.
The expansion reflects Cardinal Health’s strategic focus on meeting both current and anticipated future demand. According to company executives, increasing production capacity is essential not only to serve existing customers but also to prepare for the commercialization of new therapies currently in development.
Shane Thrasher, Vice President of Radiopharmaceutical Manufacturing within Cardinal Health’s Nuclear & Precision Health Solutions (NPHS) division, emphasized the importance of the initiative. He noted that scaling up Ac-225 production represents a significant step forward for both the industry and patients, ensuring that supply can keep pace with innovation in cancer treatment.
Shine Technologies Advances Global Isotope Supply
At the same time, Shine Technologies—a key supplier to Cardinal Health—is also making strides in isotope production. The company recently announced that it has begun exporting lutetium-177 (Lu-177), another critical medical isotope, from its production facility in Wisconsin to China. The exports are being conducted in partnership with Chinese radiopharmaceutical firm C-Ray.
Lutetium-177 is widely used in targeted radiotherapy for cancers such as neuroendocrine tumors and prostate cancer. Shine’s ability to produce and export this isotope underscores the growing capabilities of U.S.-based manufacturers, even as they work to address domestic supply challenges.
The move also highlights the dual nature of the current market: while U.S. companies aim to strengthen internal supply chains, they are simultaneously competing and collaborating on a global scale.
Reducing Dependence on Overseas Reactors
One of the key drivers behind these developments is the longstanding dependence of the U.S. on foreign nuclear reactors for essential medical isotopes. Many of these reactors are aging, and unexpected shutdowns have historically led to supply disruptions worldwide.
Efforts to localize production have gained momentum in recent years, supported in part by policy initiatives aimed at boosting domestic manufacturing. The push aligns with broader governmental goals to enhance supply chain resilience in critical sectors, including healthcare and advanced technologies.
Executives at Cardinal Health have repeatedly emphasized the importance of domestic production. Mike Pintek, President of the company’s NPHS division, previously noted that increasing U.S.-based manufacturing would provide significant benefits, including improved reliability and reduced exposure to global supply risks.
Strategic Investments and Long-Term Vision
Cardinal Health’s recent announcement is not an isolated move but part of a broader, long-term strategy. The company has been signaling its commitment to expanding radiopharmaceutical production for some time. In earlier earnings calls, CEO Jason Hollar highlighted ongoing investments in U.S. manufacturing capacity, particularly for radio diagnostics used in detecting cancer, coronary artery disease, and neurological conditions such as Alzheimer’s disease.
These investments are designed to position the company at the forefront of a rapidly evolving market. As new radiopharmaceutical therapies receive regulatory approval and enter commercial use, demand for isotopes like Ac-225 and Lu-177 is expected to increase dramatically.
Restoring U.S. Leadership in Nuclear Medicine
For industry leaders like Shine Technologies, the push toward domestic production is about more than just meeting demand—it’s about reclaiming a leadership role in a field that originated in the United States.
Shine CEO Greg Piefer has pointed out that many of the foundational technologies behind nuclear medicine were developed in the U.S., yet production has largely shifted overseas over the decades. Rebuilding domestic capabilities, he argues, would not only strengthen the national healthcare system but also ensure greater stability for global supply chains.
Piefer has also emphasized the importance of preventing shortages, which can have serious consequences for patients relying on timely diagnostic scans and treatments. By expanding production within the U.S., companies can reduce the risk of disruptions and improve access to life-saving therapies.
Challenges and Opportunities Ahead
Despite the progress being made, significant challenges remain. Building and maintaining facilities capable of producing medical isotopes is complex and costly, requiring specialized infrastructure, regulatory approvals, and highly skilled personnel. Additionally, scaling up production to meet global demand will require sustained investment and collaboration across the public and private sectors.
At the same time, the opportunities are substantial. The global radiopharmaceutical market is projected to grow rapidly over the coming years, driven by advances in precision medicine and increasing adoption of targeted therapies. Companies that can secure reliable isotope supply chains will be well-positioned to capitalize on this growth.
A Turning Point for the Industry
The recent announcements from Cardinal Health and Shine Technologies signal a pivotal moment for the radiopharmaceutical industry. As demand continues to rise, the shift toward domestic production could reshape the global landscape, reducing dependence on foreign sources and enhancing the resilience of healthcare systems.
Ultimately, these efforts are about more than industrial strategy—they are about ensuring that patients have timely access to advanced diagnostic tools and life-saving treatments. By investing in domestic capabilities today, U.S. companies are laying the groundwork for a more secure and innovative future in nuclear medicine.
About
Cardinal Health foreshadowed the move in recent earnings calls: Last August, CEO Jason Hollar said Cardinal Health was increasing US manufacturing capacity,” and in October, he told investors that the company was “expanding production of key radio diagnostics for the detection of cancer, coronary artery disease, and Alzheimer’s.”
As Shine CEO Greg Piefer told Morning Brew last year, making the US the nucleus of radiopharmaceutical manufacturing wouldn’t just be bringing production stateside — it would also return it to where it started. As it stands, a medical isotope used in most procedures that rely on nuclear medicine is produced outside the US.
We invented these technologies in the United States,” Piefer said. “It’ll return production leadership to the United States. But more importantly, it’ll prevent shortages in the United States, and, frankly, all of the West.”
